This study was followed up by a phase I/II trial (MESODEC) in which treatment-naïve patients received WT1-targeting DC-therapy during chemotherapy, followed by pleurectomy/decortication (P/D) in the case of a resectable tumor (NCT02649829). This evidence concerns the gene WT1 and neoplasm.